Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses

PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
Actinic Keratosis
Interventions
DRUG

PEP005

Trial Locations (24)

10025

St. Luke's/Roosevelt Hospital Center Dermatology, New York

10029

Mount Sinai Hospital School of Medicine, New York

29621

Radiant Research, Anderson

29651

Radiant Research, Greer

30263

Medaphase, Inc, Newnan

32073

Park Avenue Dermatology, PA, Orange Park

32204

North Florida Dermatology Associates P.A., Jacksonville

32308

Dermatology Associates of Tallahassee, Tallahassee

33134

Dermatology Associates and Research, Coral Gales

33401

Palm Beach Aesthetics, West Palm Beach

34711

Advanced Dermatology and Cosmetic Surgery, Clermont

35801

Medical Affiliated Research Center, Inc., Huntsville

43212

Radiant Research, Columbus

48322

Henry Ford Health Center- Farmington Road, West Bloomfield

71913

Burke Pharmaceutical Research, Hot Springs

75703

Dermatology Associates of Tyler, Tyler

84124

Dermatology Research Centre, Salt Lake City

85710

Radiant Research, Tucson

97223

Oregon Medical Research, Centre9495 Southwest Locust St., Suite G Portland

99204

Skokane Dermatology Clinic, PLLP., Spokane

30078-3250

Gwinnett Clinical Research Centre, Inc, Snellville

87106-5239

Academic Dermatology Associates, Albuquerque

45219-4215

University Dermatology Consultants, Inc., Dermatology Clinical Research Center, Cincinnati

78229-3409

Dermatology Clinical Research Center of San Antonio, San Antonio

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Peplin

INDUSTRY

NCT00375739 - Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses | Biotech Hunter | Biotech Hunter